Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.

MLA

Zaman, Khalequ, et al. “Immunogenicity of Type 2 Monovalent Oral and Inactivated Poliovirus Vaccines for Type 2 Poliovirus Outbreak Response: An Open-Label, Randomised Controlled Trial.” The Lancet. Infectious Diseases, vol. 18, no. 6, June 2018, pp. 657–65. EBSCOhost, https://doi.org/10.1016/S1473-3099(18)30113-0.

APA

Zaman, K., Estívariz, C. F., Morales, M., Yunus, M., Snider, C. J., Gary, H. E., Jr, Weldon, W. C., Oberste, M. S., Wassilak, S. G., Pallansch, M. A., & Anand, A. (2018). Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial. The Lancet. Infectious Diseases, 18(6), 657–665. https://doi.org/10.1016/S1473-3099(18)30113-0

Chicago

Zaman, Khalequ, Concepción F Estívariz, Michelle Morales, Mohammad Yunus, Cynthia J Snider, Howard E Gary Jr, William C Weldon, et al. 2018. “Immunogenicity of Type 2 Monovalent Oral and Inactivated Poliovirus Vaccines for Type 2 Poliovirus Outbreak Response: An Open-Label, Randomised Controlled Trial.” The Lancet. Infectious Diseases 18 (6): 657–65. doi:10.1016/S1473-3099(18)30113-0.